There was a significant interaction between hs-cTnT level and treatment group with respect to death or heart failure hospitalization (Pinteraction=0.04) and heart failure hospitalization alone (Pinteraction=0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. This evidence concerns the gene TNNT2 and heart failure.